STOCK TITAN

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ultragenyx (NASDAQ: RARE) reported an inducement equity grant under Nasdaq Listing Rule 5635(c)(4).

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Ultragenyx (NASDAQ: RARE) reported an inducement equity grant under Nasdaq Listing Rule 5635(c)(4).

The company granted 17,567 restricted stock units of common stock to 11 newly hired non-executive officers on May 16, 2026, under the Ultragenyx Employment Inducement Plan. The RSUs vest over four years, in 25% annual installments.

Loading...
Loading translation...
Argus May 26 session
-1.07% close to close Open Argus
Details

News Market Reaction – RARE

On May 26, the first trading day after this news, RARE closed 1.07% below the previous close.

Data tracked by StockTitan Argus for the May 26 session.

Key Figures

RSU grant size: 17,567 restricted stock units Employees granted: 11 employees Vesting schedule: 4 years +1 more
RSU grant size
17,567 restricted stock units
Inducement grant to newly hired non-executive officers
Employees granted
11 employees
Newly hired non-executive officers receiving RSU awards
Vesting schedule
4 years
RSUs vest in four equal annual installments
Annual vesting rate
25% per year
Portion of RSUs vesting on each grant-date anniversary

Historical Context

5 past events · Latest: May 06
5 events
  1. May 06

    Conference participation

    24h Move
    +0.8%

    Announcement of participation in Bank of America 2026 healthcare conference.

  2. May 05

    Earnings and guidance

    24h Move
    +3.7%

    Q1 2026 results and reaffirmed full-year revenue guidance and profitability path.

  3. Apr 29

    Earnings call notice

    24h Move
    -1.4%

    Scheduling of Q1 2026 results call and webcast information.

  4. Apr 24

    Inducement grant

    24h Move
    -0.5%

    Inducement RSU grant to new non-executive officers under Nasdaq Rule 5635(c)(4).

  5. Apr 02

    Regulatory milestone

    24h Move
    +4.8%

    FDA acceptance of UX111 BLA resubmission with PDUFA date set.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

restricted stock units, nasdaq listing rule 5635(c)(4), inducement plan
3 terms
restricted stock units financial
"reported the grant of 17,567 restricted stock units of the company’s common stock"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
nasdaq listing rule 5635(c)(4) regulatory
"as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
inducement plan financial
"granted under the Ultragenyx Employment Inducement Plan, with a grant date of May 16, 2026"
An inducement plan is a program a company creates to encourage employees or new hires to stay or join by offering special benefits or rewards. It’s like a company giving extra bonuses or perks to persuade someone to choose their job over others, helping the company attract and keep talented workers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

NOVATO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 17,567 restricted stock units of the company’s common stock to 11 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of May 16, 2026, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date, subject to the employee being continuously employed by the company as of such vesting dates.

About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement grant did Ultragenyx (NASDAQ: RARE) announce on May 22, 2026?

Ultragenyx announced an inducement grant of 17,567 restricted stock units to 11 newly hired non-executive officers. According to Ultragenyx, these RSUs were granted under the Ultragenyx Employment Inducement Plan with a grant date of May 16, 2026, subject to time-based vesting.

How many restricted stock units did Ultragenyx grant under its Employment Inducement Plan?

Ultragenyx granted 17,567 restricted stock units of its common stock as employment inducement awards. According to Ultragenyx, these RSUs were approved by the board’s compensation committee and are intended as a material inducement for new non-executive officers to join the company.

How do the Ultragenyx (RARE) inducement restricted stock units vest over four years?

The Ultragenyx inducement restricted stock units vest in four equal annual installments. According to Ultragenyx, 25% of the underlying shares vest on each anniversary of the May 16, 2026 grant date, contingent on the employee’s continuous employment at each vesting date.

Who received the Ultragenyx May 16, 2026 inducement RSU grants?

The inducement RSU grants were awarded to 11 newly hired non-executive officers at Ultragenyx. According to Ultragenyx, these grants were approved by the compensation committee as a material inducement for the new employees to enter into employment with the company.

Keep reading